Work-related musculoskeletal disorders (WMSDs) represent a significant occupational health challenge among healthcare professionals globally, posing substantial threats to physical and mental well-being as well as work sustainability. Adopting preventive behaviors—including ergonomic postural adjustments, optimized work-rest scheduling, proper use of protective and assistive equipment, and regular physical activity—is essential for mitigating the risk of WMSDs. Guided by the social ecological model, the review synthesized current evidence on the determinants of WMSDs preventive behaviors across four levels: intrapersonal characteristics, work environment conditions, interpersonal support, and policy/institutional factors. The findings suggest that higher educational attainment, favorable health-related behavioral patterns, optimized ergonomic work environments, adoption of supportive collaborative systems, strong organizational support, as well as policy safeguards facilitate preventive behavior adoption. Conversely, limited prevention-related knowledge, low risk perception, insufficient physical activity, excessive workload, lack of appropriate protective equipment, inadequate ergonomic training, a prevailing culture of presenteeism, and inadequate policy implementation constitute significant barriers. Multi-dimensional intervention strategies targeting these determinants are warranted to enhance preventive behaviors, reduce the risk of WMSDs, and strengthen occupational health protection for healthcare professionals.

Objective:To investigate the role of the Smad3 signaling pathway in the process of silica-induced epithelial-mesenchymal transition (EMT) .Methods:In September 2022, lung epithelial cells (BEAS-2B) were exposed to different concentrations of silica suspension (0, 50, 100, and 150 μg/ml) for 6 and 12 hours. Additionally, SIS3, a specific inhibitor of phosphorylated Smad3 (p-Smad3) , was utilized to establish the p-Smad3 inhibition model. The cells were divided into four groups: blank control gruop, silica group, SIS3 intervention group, and SIS3 +silica group. Cell morphology was observed using an inverted fluorescence microscope, while cell viability was assessed using a Cell Counting Kit-8 (CCK-8) . The mRNA and protein expression levels of E-cadherin (E-Cad) , N-cadherin (N-Cad) , Vimentin, Smad3, and p-Smad3 were analyzed by Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting, respectively. Differences between two groups were compared using Student's t-test, and multiple group comparisons were analyzed using a one-way analysis of variance with the Student-Newman-Keuls test.Results:Compared with the blank control group, the morphology of BEAS-2B cells shifted from epithelial to mesenchymal cell-like following silica exposure, and the cell viability of BEAS-2B cells declined after exposure to 150 μg/ml silica for 6 and 12 hours. Furthermore, silica exposure led to significant reductions in mRNA and protein expression levels of the epithelial cellular marker (E-Cad) in BEAS-2B cells, accompanied by increased expressions of interstitial cellular markers (N-Cad and Vimentin) . Importantly, the level of p-Smad3/Smad3 expression levels was also elevated in silica-treated cells ( P<0.05) . Compared to the blank control group, the level of p-Smad3/Smad3 expression levels was significantty reduced. Moreover, compared to the silica group, the protein expression levels of N-Cad and Vimentin in the cell of the SIS3+silica group were significantly reduced, while the E-Cad expression was increased ( P<0.05) . Conclusion:Silica exposure can prmote the epithelial mesenchymaol transformotion process by activating smod3 signa ling pathuay, and in hibiting smad3 signa ling pathuay can effctively alleviate the occurrence of epithelial mesenchymal transformation process.

The development of breast pathology technology provides basic support for precise typing and individualized treatment of breast cancer.Precision in breast cancer diagnosis and management is evolving as a fundamental trend,with the advent of novel therapeutic agents necessitating enhanced accuracy in pathological diagnostic evaluations.The application of trastuzumab deruxtecan(T-DXd)has offered new therapies for breast cancer patients with human epidermal growth factor receptor 2(HER2)-low and HER2-ultra low status.With the refinement of the classification for HER2 expression status,as a traditional detection method,the efficacy of immunohistochemistry(IHC)has been challenged.In addition,HER2-low has poor interpretation consistency,with spatial and temporal heterogeneity,which is affected by the storage time of the blank slides.Nowadays,finding auxiliary methods that can effectively improve the testing efficiency and interpretation accuracy of IHC as well as new accessible HER2 detection methods are important exploration directions.Whether HER2-low can be considered an independent molecular type of breast cancer has become an important issue with the update of treatments and the progress of new drugs.However,the answer is no at this time due to the absence of distinct and stable biological and pathological features and the lack of specific therapeutic benefit and prognostic relevance.With the widespread adoption and advancement of genomic profiling technologies,multiple causative genetic mutations associated with breast cancer have been identified.The development and clinical application of targeted drugs have elevated genomic profiling to an increasingly pivotal role in clinical decision-making for breast cancer treatment.In recent years,multiple inhibitors targeting the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)signaling pathway(PAM pathway)have demonstrated promising therapeutic efficacy in hormone receptor(HR)positive/HER2-negative breast cancer.The clinical prioritization of PIK3CA/AKT1/PTEN molecular profiling has been intensified,and the trend is to move forward the time of the initial test.Tumor tissue samples are preferred for testing,and plasma samples can be used as a necessary supplement.Samples from primary or recurrent tumors are considered to have similar testing efficacy and can be selected as appropriate.BRCA mutation is one of the common types of genetic mutations in breast cancer.While current guidelines vary in specifics regarding target populations,they universally prioritize clinical parameters including diagnostic age,family history,and treatment response to identify patients who have elevated BRCA mutation risks and may benefit from poly(ADP-ribose)polymerase(PARP)inhibitor therapy.This article summarized the latest advances and controversies in breast pathology techniques,focusing on the diagnostic criteria and methodological limitations in detecting HER2-low and HER2-ultra low breast cancers,therapeutic progress in PAM pathway-aberrant breast cancer,and the target population for detecting BRCA gene mutations.

Ursodeoxycholic acid (UDCA) is a naturally occurring, low-toxicity, and hydrophilic bile acid (BA) in the human body that is converted by intestinal flora using primary BA. Solute carrier family 7 member 11 (SLC7A11) functions to uptake extracellular cystine in exchange for glutamate, and is highly expressed in a variety of human cancers. Retroperitoneal liposarcoma (RLPS) refers to liposarcoma originating from the retroperitoneal area. Lipidomics analysis revealed that UDCA was one of the most significantly downregulated metabolites in sera of RLPS patients compared with healthy subjects. The augmentation of UDCA concentration (≥25 μg/mL) demonstrated a suppressive effect on the proliferation of liposarcoma cells. [¹⁵N₂]-cystine and [¹³C₅]-glutamine isotope tracing revealed that UDCA impairs cystine uptake and glutathione (GSH) synthesis. Mechanistically, UDCA binds to the cystine transporter SLC7A11 to inhibit cystine uptake and impair GSH de novo synthesis, leading to reactive oxygen species (ROS) accumulation and mitochondrial oxidative damage. Furthermore, UDCA can promote the anti-cancer effects of ferroptosis inducers (Erastin, RSL3), the murine double minute 2 (MDM2) inhibitors (Nutlin 3a, RG7112), cyclin dependent kinase 4 (CDK4) inhibitor (Abemaciclib), and glutaminase inhibitor (CB839). Together, UDCA functions as a cystine exchange factor that binds to SLC7A11 for antitumor activity, and SLC7A11 is not only a new transporter for BA but also a clinically applicable target for UDCA. More importantly, in combination with other antitumor chemotherapy or physiotherapy treatments, UDCA may provide effective and promising treatment strategies for RLPS or other types of tumors in a ROS-dependent manner.

Objective To investigate the clinical features of chronic hepatitis C(CHC)patients with hepatitis C virus genotype 3(HCV GT3)infection and the risk factors for disease progression.Methods A multicenter retrospective cohort study was conducted among 1 002 CHC patients from 11 clinical centers in Northwest China from December 2017 to November 2023,and according to their genotype,they were divided into GT1,GT2,GT3,and GT6 groups.Clinical features were compared between the patients with different genotypes.The one-way analysis of variance was used for comparison of normally distributed continuous data between groups,and the Scheffe test was used for further comparison between two groups.The Kruskal-Wallis H test was used for comparison of data with skewed distribution between groups;the chi-square test or Fisher test was used for comparison of categorical data between groups.The multivariate logistic regression analysis was used to explore the influencing factors for the progression of CHC to liver cirrhosis.Results In terms of the genotype,there were 427 patients with GT1 infection,242 with GT2 infection,299 with GT3 infection(210 patients with GT3a infection,87 with GT3b infection,and 2 with unclassified genotype),and 34 with GT6 infection.The patients with GT3 infection had a significantly younger age than those with GT1 infection(51.3±0.5 years vs 53.2±0.6 years,P<0.05)or GT2 infection(51.3±0.5 years vs 53.7±0.8 years,P<0.05),and for the patients with liver cirrhosis,the patients with GT3 infection had a significantly younger age than those with GT1 infection(52.1±0.5 years vs 59.4±0.9 years,P<0.001)or GT2 infection(52.1±0.5 years vs 58.1±1.1 years,P<0.001).Among the patients with GT3 infection,male patients accounted for 77.9%and the patients with liver cirrhosis accounted for 46.2%,which were significantly higher than those among the patients with GT1,GT2 or GT6 infection(all P<0.001).At baseline,the patients with GT3 infection had significantly higher levels of alanine aminotransferase(ALT)and aspartate aminotransferase(AST)than those with GT1 or GT2 infection,significantly higher aspartate aminotransferase-to-platelet ratio index(APRI)and fibrosis-4(FIB4)than those with GT1,GT2 or GT6 infection,a significantly lower platelet count(PLT)than those with GT2 or GT6 infection,a significantly higher level of alpha-fetoprotein than those with GT2 or GT6 infection,and a significantly lower level of albumin(Alb)than those with GT6 infection(all P<0.05).There were no significant differences between the patients with GT3a infection and those with GT3b infection in age,sex,the proportion of patients with liver cirrhosis,comorbidities,HCV RNA quantification,PLT,ALT,AST,alkaline phosphatase,Alb,APRI,and FIB-4(all P>0.05).The multivariate logistic regression analysis showed that PLT≤150×109/L(odds ratio[OR]=10.72,95%confidence interval[CI]:5.76-35.86,P<0.001)and Alb≤35 g/L(OR=3.74,95%CI:1.22-11.45,P=0.021)were risk factors for liver cirrhosis.Conclusion Most CHC patients with GT3 infection are male in Northwest China,and compared with the patients with other genotypes,such patients tend to have a younger age of onset and higher degrees of liver inflammation activity and fibrosis.Low PLT and a low level of Alb are risk factors for progression to liver cirrhosis in CHC patients with GT3 infection.

Objective To develop a predictive model for assessment of the risk of the patients on prolonged mechanical ventilation after coronary artery bypass grafting with extracorporeal circulation.Methods A convenience sampling method was employed to select 2 334 patients who received the coronary artery bypass grafting(CABG)with extracorporeal circulation in our hospital from January 2021 to December 2023 as the study subjects.Preoperative,intraoperative and postoperative data were collected through structured queries from the electronic medical record system of hospital.The study subjects were randomly divided into a training set(n=1 633)and a validation set(n=701)following a 3:1 ratio.A risk prediction model was established using Logistic regression based on the training set data.Model fit was assessed using Hosmer-Lemeshow test,and predictive performance of the model was evaluated with the area under curve(AUC)of the receiver operating characteristic(ROC)curve.Results A total of 2,334 patients were included,of whom 215(9.2%)experienced the prolonged mechanical ventilation(>24 hours).The model developed from the training set identified seven factors that contributed to a prolonged mechanical ventilation:age(OR=1.03),body mass index(BMI,OR=1.14),time of extracorporeal circulation(OR=1.01),intraoperative blood transfusion(OR=4.15),postoperative serum total bilirubin(OR=1.08),postoperative serum albumin(OR=0.92)and postoperative re-sternotomy(OR=5.49).The AUC of the model for prediction of prolonged mechanical ventilation after CABG with extracorporeal circulation was 0.761,with a 95%CI of 0.716-0.806,a maximum Youden index of 0.105,a sensitivity of 77.94%,and a specificity of 64.38%.Validation using the validation set data yielded an AUC of 0.733,with a 95%CI of 0.662-0.804,a sensitivity of 75.32%,a specificity of 57.97%,and a predictive accuracy of 73.61%.Conclusion The risk prediction model developed in this study for prolonged mechanical ventilation after a CABG with extracorporeal circulation demonstrates a good predictive performance.It provides a reference for the nurses to identify the patient in high-risk of prolonged mechanical ventilation after a CABG with extracorporeal circulation and to implement preventive nursing measures.

Early-stage treatment of malignant tumors has a significant effect on improving the prognosis. In ASCO and ESMO 2024, several important advancements have been made in the field of systemic therapy for early-stage breast cancer, particularly in the diversification of treatment plans and the individualization of strategies for different molecular subtypes of breast cancer. The importance of adjuvant endocrine therapy (AET) has been highlighted on treating hormone receptor positive/human epidermal growth factor receptor 2 negative early breast cancer.The adjuvant therapy with Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has been proven successful in treating HR+/HER2- early breast cancer. Neoadjuvant immunotherapy targeting early triple positive breast cancer (TNBC) has shown unique advantages. The possibility of having down-grade chemotherapy safely in treating HR+/HER2+ stage breast cancer has been explored.

Objective To investigate the association between UGT1A1 inhibitors-induced liver injury(DILI)and UGT1A1 gene polymorphisms through a pharmacogenomics approach.Methods Information on relevant drugs that may induce liver injury,blood routine tests,and liver function tests was collected from hospitalized patients diagnosed with DILI between June 2022 and June 2024.Relevant databases were searched to categorize DILI-associated drugs into UGT1A1 enzyme inhibitors and those without interaction with UGT1A1.Sanger sequenc-ing or MassARRAY SNP typing technology was utilized to detect and genotype the UGT1A1 gene.Results A total of 219 patients with drug-induced liver injury(DILI)were enrolled,including 98 males,with a mean age of 46.32±14.95 years.A literature search of relevant databases revealed that 20 drugs(16.26%,20/123)associated with DILI had inhibitory effects on the UGT1A1 enzyme.The proportion of DILI cases related to UGT1A1 inhibitors was 60.73%(133/219).Compared to non-UGT1A1 inhibitor-related DILI group,the UGT1A1 inhibitor-related DILI group exhibited significantly higher levels of ALT,AST,ALP,and GGT(P<0.05),while no significant differences were observed in age,gender,TBIL,IBIL,WBC,Hb,PLT,injury type,or injury grade(P>0.05).The prevalence of UGT1A1 polymorphisms was significantly higher in the UGT1A1 inhibitor-related DILI group(68.42%)com-pared to the non-UGT1A1 inhibitor-related DILI group(51.16%),with an odds ratio(OR)of 2.068(95%CI:1.183 to 3.617;χ2=6.58,P=0.010).There was also a significant difference in the distribution of genotypes between the UGT1A1 inhibitor-related and non-UGT1A1 inhibitor-related DILI groups(χ2=9.60,P=0.022).Univariate logistic regression analysis indicated that ALT and UGT1A1*6 were associated with UGT1A1 inhibitor-related DILI,while multivariate analysis confirmed that UGT1A1*6 was independently associated with UGT1A1 inhibitor-related DILI[OR(95%CI)=3.143(1.398 to 7.067),P=0.006].Conclusion The UGT1A1*6 allele increases the susceptibility to drug-induced liver injury(DILI)associated with UGT1A1 inhibitory drugs.

Breast cancer is one of the most common malignant tumors in women,which posing a serious threat to women's health.With the deepening of the concept of precision treatment,the surgical treatment of breast cancer has made great progress.However,new techniques and ideas have also brought about many controversies.With the popularization of the"de-escalation"concept,performing sentinel lymph node biopsy(SLNB)as an alternative to axillary lymph node dissection(ALND)in specific patients has emerged as a trend.For clinically node-negative early-stage breast cancer with 1-2 positive sentinel lymph nodes(SLN),ALND can be safely omitted with effective axillary radiotherapy.Patients with clinically node-positive early-stage breast cancer can forgo ALND if SLNB proves that they have been downstaged to cN0 by neoadjuvant treatment(NAT).As the two most commonly used axillary surgical staging techniques in SLNB for post-NAT patients,dual-tracer of lymph nodes and targeted axillary dissection(TAD)are considered consistent in oncologic safety.Prophylactic mastectomy is a significant intervention to reduce breast cancer incidence among women at high risk.It has been confirmed that contralateral prophylactic mastectomy(CPM)can reduce the incidence of contralateral breast cancer(CBC)but does not significantly improve the survival outcomes.Enhancing the accessibility of risk assessment methods and establishing precise and effective risk prediction models have emerged as important issues.Above all,the development of breast surgery shows a refinement of risk management and damage control,striving to achieve a safe"de-escalation"in surgical modalities based on individualized treatment.This article summarized and analyzed relevant studies on the aspect of the surgery techniques for breast cancer,aiming to provide new insights into optimizing the clinical diagnosis and treatment of breast cancer.

Breast cancer is one of the most common malignant tumors in women,which posing a serious threat to women's health.With the deepening of the concept of precision treatment,the surgical treatment of breast cancer has made great progress.However,new techniques and ideas have also brought about many controversies.With the popularization of the"de-escalation"concept,performing sentinel lymph node biopsy(SLNB)as an alternative to axillary lymph node dissection(ALND)in specific patients has emerged as a trend.For clinically node-negative early-stage breast cancer with 1-2 positive sentinel lymph nodes(SLN),ALND can be safely omitted with effective axillary radiotherapy.Patients with clinically node-positive early-stage breast cancer can forgo ALND if SLNB proves that they have been downstaged to cN0 by neoadjuvant treatment(NAT).As the two most commonly used axillary surgical staging techniques in SLNB for post-NAT patients,dual-tracer of lymph nodes and targeted axillary dissection(TAD)are considered consistent in oncologic safety.Prophylactic mastectomy is a significant intervention to reduce breast cancer incidence among women at high risk.It has been confirmed that contralateral prophylactic mastectomy(CPM)can reduce the incidence of contralateral breast cancer(CBC)but does not significantly improve the survival outcomes.Enhancing the accessibility of risk assessment methods and establishing precise and effective risk prediction models have emerged as important issues.Above all,the development of breast surgery shows a refinement of risk management and damage control,striving to achieve a safe"de-escalation"in surgical modalities based on individualized treatment.This article summarized and analyzed relevant studies on the aspect of the surgery techniques for breast cancer,aiming to provide new insights into optimizing the clinical diagnosis and treatment of breast cancer.